- Home
- ATLCP vs OSRHW Comparison
ATLCP vs OSRHW Comparison
Compare ATLCP & OSRHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
ATLCP
Atlanticus Holdings Corporation 7.625% Series B Cumulative Perpetual Preferred Stock no par value per share
Company Overview
Basic Information| Metric | ATLCP | OSRHW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 417 | 21 |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | ATLCP | OSRHW |
|---|---|---|
| Price | $24.05 | $0.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | N/A |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | N/A |
| 52 Week High | N/A | N/A |
Technical Indicators
Market Signals| Indicator | ATLCP | OSRHW |
|---|---|---|
| Relative Strength Index (RSI) | 53.43 | N/A |
| Support Level | $23.73 | N/A |
| Resistance Level | $24.20 | N/A |
| Average True Range (ATR) | 0.20 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 74.58 | 0.00 |
Price Performance
Historical ComparisonAbout ATLCP Atlanticus Holdings Corporation 7.625% Series B Cumulative Perpetual Preferred Stock no par value per share
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About OSRHW OSR Holdings Inc. Warrant
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.